Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation  Treated with Ensartinib: A Case Report and Literature Review].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Jan 2023

Lv Donglai, Xu Chunwei, Wang Chong, Sang Qiuju

Abstract excerpt

Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer. Anaplastic lymphoma kinase (ALK)-positive NSCLC accounts for only 2%-5% of all NSCLC cases, and is almost exclusively detected in patients with lung adenocarcinoma. Thus, ALK testing is not routinely performed in the LSCC population, and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Cytoskeletal Proteins

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 36792084
DOI: 10.3779/j.issn.1009-3419.2023.106.03
PMCID: PMC9987096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation Treated with Ensartinib: A Case Report and Literature Review].PMID 36792084Read ↗

Lung Squamous Cell Carcinoma With Anaplastic Lymphoma Kinase Rearrangement and TP53 Co-mutation Treated Successfully with Ensartinib: A Case ReportSemantic proximity Read ↗

Coexistence of a primary ALK-positive and MET14 exon skipping mutation double-fusion in one patient with NSCLC and response to crizotinib: A case report and literature review.Semantic proximity Read ↗

[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].Semantic proximity Read ↗

EML4‑ALK fusion gene in non‑small cell lung cancer (Review)Semantic proximity Read ↗

[Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib: A Case Report and Literature Review].Semantic proximity Read ↗

[Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].Semantic proximity Read ↗

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.Semantic proximity Read ↗

[Chinese Expert Consensus on Diagnosis and Treatment of Non-small Cell Lung Cancer with MET Abnormality (2026 Version)].Semantic proximity Read ↗

Efficacy and Safety of Ensartinib in the Treatment of Non-Small Cell Lung Cancer: A Systematic Review of Clinical TrialsSemantic proximity Read ↗

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Semantic proximity Read ↗

Osimertinib plus Chemotherapy versus Osimertinib for Patients with Advanced NSCLC Concomitant EGFR and TP53 Mutations: A Prospective Cohort StudySemantic proximity Read ↗

[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.